Your browser doesn't support javascript.
loading
Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma.
González-Borja, Iranzu; Viúdez, Antonio; Alors-Pérez, Emilia; Goñi, Saioa; Amat, Irene; Ghanem, Ismael; Pazo-Cid, Roberto; Feliu, Jaime; Alonso, Laura; López, Carlos; Arrazubi, Virginia; Gallego, Javier; Pérez-Sanz, Jairo; Hernández-García, Irene; Vera, Ruth; Castaño, Justo P; Fernández-Irigoyen, Joaquín.
Affiliation
  • González-Borja I; OncobionaTras Lab, Navarrabiomed, Navarra University Hospital, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Spain.
  • Viúdez A; OncobionaTras Lab, Navarrabiomed, Navarra University Hospital, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Spain.
  • Alors-Pérez E; Medical Oncology Department, Navarra University Hospital, 31008 Pamplona, Spain.
  • Goñi S; Maimonides Biomedical Research Institute of Córdoba, 14004 Córdoba, Spain.
  • Amat I; Department of Cell Biology, Physiology, and Immunology, University of Córdoba, 14071 Córdoba, Spain.
  • Ghanem I; Reina Sofía University Hospital, 14004 Córdoba, Spain.
  • Pazo-Cid R; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, (CIBERobn), 14004 Córdoba, Spain.
  • Feliu J; OncobionaTras Lab, Navarrabiomed, Navarra University Hospital, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Spain.
  • Alonso L; Pathology Department, Navarra University Hospital, 31008 Pamplona, Spain.
  • López C; Medical Oncology Department, La Paz University Hospital, 28046 Madrid, Spain.
  • Arrazubi V; Medical Oncology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
  • Gallego J; Medical Oncology Department, La Paz University Hospital, 28046 Madrid, Spain.
  • Pérez-Sanz J; Pathology Department, Navarra University Hospital, 31008 Pamplona, Spain.
  • Hernández-García I; Medical Oncology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
  • Vera R; Medical Oncology Department, Navarra University Hospital, 31008 Pamplona, Spain.
  • Castaño JP; Medical Oncology Department, Hospital General Universitario de Elche, 03203 Elche, Spain.
  • Fernández-Irigoyen J; OncobionaTras Lab, Navarrabiomed, Navarra University Hospital, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Spain.
Cancers (Basel) ; 14(23)2022 Dec 05.
Article in En | MEDLINE | ID: mdl-36497475
ABSTRACT
Despite its relative low incidence, PDAC is one of the most aggressive and lethal types of cancer, being currently the seventh leading cause of cancer death worldwide, with a 5-year survival rate of 10.8%. Taking into consideration the necessity to improve the prognosis of these patients, this research has been focused on the discovery of new biomarkers. For this purpose, patients with BL and resectable disease were recruited. Serum cytokines and growth factors were monitored at different time points using protein arrays. Immune cell populations were determined by flow cytometry in peripheral blood as well as by immunohistochemistry (IHC) in tumor tissues. Several cytokines were found to be differentially expressed between the study subgroups. In the BL disease setting, two different scores were proven to be independent prognostic factors for progression-free survival (PFS) (based on IL-10, MDC, MIF, and eotaxin-3) and OS (based on eotaxin-3, NT-3, FGF-9, and IP10). In the same context, CA19-9 was found to play a role as independent prognostic factor for OS. Eotaxin-3 and MDC cytokines for PFS, and eotaxin-3, NT-3, and CKß8-1 for OS, were shown to be predictive biomarkers for nab-paclitaxel and gemcitabine regimen. Similarly, oncostatin, BDNF, and IP10 cytokines were proven to act as predictive biomarkers regarding PFS, for FOLFIRINOX regimen. In the resectable cohort, RANTES, TIMP-1, FGF-4, and IL-10 individually differentiated patients according to their cancer-associated survival. Regarding immune cell populations, baseline high levels of circulating B lymphocytes were related to a significantly longer OS, while these levels significantly decreased as progression occurred. Similarly, baseline high levels of helper lymphocytes (CD4+), low levels of cytotoxic lymphocytes (CD8+), and a high CD4/CD8 ratio, were related to a significantly longer PFS. Finally, high levels of CD4+ and CD8+ intratumoural infiltration was associated with significantly longer PFS. In conclusion, in this study we were able to identify several prognostic and predictive biomarker candidates in patients diagnosed of resectable or BL PDAC.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cancers (Basel) Year: 2022 Document type: Article Affiliation country: Spain